Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PetVivo HoldingsPETV +1.59%40 Debt-to-Equity is 0.17 as of Mar. 2026, which is 55% above its 10-year median of 0.11. GuruFocus rates PETV with a GF Score™ of 40/100 and a GF Value™ of $0.50 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, PetVivo Holdings ranks better than 57.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PetVivo Holdings's Debt-to-Equity or its related term are showing as below:
PETV'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.82 Med: 0.11 Max: 1.99
Current: 0.17
During the past 13 years, the highest Debt-to-Equity Ratio of PetVivo Holdings was 1.99. The lowest was -0.82. And the median was 0.11.
PETV's Debt-to-Equity is ranked better than 57.16% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs PETV: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PetVivo Holdings Debt-to-Equity Related Terms
PetVivo Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETV vs FOFA, ARAY, GTHP: Debt-to-Equity Comparison
For the Medical Devices subindustry, PetVivo Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetVivo Holdings (PETV) has a Debt-to-Equity of 0.17 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PetVivo Holdings and its competitors. This is 55% above median its historical median of 0.11. According to the industry distribution chart, PetVivo Holdings ranks #302 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 42.8%.
Is PetVivo Holdings' Debt-to-Equity too high?
PetVivo Holdings' current Debt-to-Equity of 0.17 is 55% above median its 10-year median of 0.11. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. PetVivo Holdings' value of 0.17 is 26.1% below this industry median. Based on the distribution chart, PetVivo Holdings ranks #302 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PetVivo Holdings has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' Debt-to-Equity compare to FOFA and ARAY?
According to the Medical Devices & Instruments industry distribution chart, PetVivo Holdings ranks #302 out of 705 companies for Debt-to-Equity. This puts PetVivo Holdings in the upper half of its industry. The industry median Debt-to-Equity is 0.23. PetVivo Holdings' value of 0.17 is 26.1% below this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 0.23, PetVivo Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PetVivo Holdings's current Debt-to-Equity of 0.17 is 26.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PetVivo Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PetVivo Holdings's current Debt-to-Equity is 0.17, which is 55% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
Based on GuruFocus' analysis, PetVivo Holdings (PETV) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.64 — trading 28% above its estimated fair value. The current Debt-to-Equity is 0.17, which is 55% above median its 10-year median of 0.11 and 26.1% below the Medical Devices & Instruments industry median of 0.23. PetVivo Holdings' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PetVivo Holdings (PETV), the current Debt-to-Equity is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetVivo Holdings (PETV) Overvalued in 2026?
Based on GuruFocus' analysis, PetVivo Holdings stock appears to be overvalued.
The current stock price of $0.64 is trading 28% above its estimated GF Value™ of $0.50.
GuruFocus considers PetVivo Holdings to be Modestly Overvalued.
Key valuation signals for PETV:
Debt-to-Equity: 0.17 (55% above median its 10-year median of 0.11)
GF Value™: $0.50 vs. price of $0.64 (28% above fair value)
Industry Position: 26.1% below the Medical Devices & Instruments median (#302 of 705)
No single metric tells the full story. See the PETV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
40GF Score
Get the complete analysis for PETV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETV has been successfully added to your 
